Thromb Haemost 1972; 27(03): 516-522
DOI: 10.1055/s-0038-1649390
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Acute Promyelocytic Leukemia in a Patient with Hemophilia

Evidence for Rapid Consumption of Clotting Factors
D. Green M. D.
1   Hematology Section, Department of Medicine, Northwestern University - McGaw Medical Center, Chicago, III
› Author Affiliations
Supported in part by USPHS Grant 1-R01-HE 12858-02 from the National Heart Institute.
Further Information

Publication History

Publication Date:
29 June 2018 (online)

Summary

Factor VIII levels are usually elevated in patients with leukemia, and recently markedly increased levels of factor VIII were described during the relapses of acute lymphoblastic leukemia in a boy with previously documented hemophilia. In this paper we describe a young man with severe classical hemophilia who developed acute promyelocytic leukemia. In contrast to the findings noted above, infused factor VIII in this patient rapidly disappeared, with a half-life of only 4-8 h (expected: 12 h). In addition, the half-life of fibrinogen was 20 h (expected: 72 h), there was marked thrombocytopenia, and decreased levels of factor V. It is suggested that the rapid consumption of factor VIII is consistent with the syndrome of “consumption coagulopathy” which was present as a complication of his acute promyelocytic leukemia.

 
  • References

  • 1 Rosenthal R. L, Lee S. L, Rosenthal N. Hypofibrinogenemia as a factor in hemorrhage in acute leukemia. Clin. Res. Proc 03: 101 1955;
  • 2 Rosenthal R. L. Acute Promyelocytic leukemia associated with hypofibrinogenemia. Blood 21: 495-508. 1963;
  • 3 Denson K. W. E. Technical Methods. In: Biggs R, MacFarlane R. G. (Eds.), Treatment of haemophilia and other coagulation disorders. 350-357 Davis; Philadelphia: 1966
  • 4 Ratnoff O. D, Menzie G. A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med 37: 316-320. 1951;
  • 5 Shanberge J. N, Matsuoka T, Fukui H. A simple method for the preparation of a substrate for a one-stage factor V assay. Techn. Bull. Regist. Med. Techn 37: 67-71. 1967;
  • 6 Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J. Immun 42: 109-116. 1941;
  • 7 Hawiger J, Niewiarowski S, Gurewich V, Thomas D. P. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J. Lab. clin. Med 75: 93-108. 1970;
  • 8 Rizza G. R, Biggs R. Blood products in the management of Haemophilia and Christmas Disease. In: Poller L. (Ed.), Recent advances in blood coagulation. 179-191 Little, Brown and Company; Boston: 1969
  • 9 Pool J. G, Gohen T, Greger W. P. Biological half-life of transfused AHG (Factor VIII) in normal man. Brit. J. Haemat 13: 822-828. 1967;
  • 10 Rausen A. R, Cruchaud A, McMillan G. W, Gitlin D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 18: 710-716. 1961;
  • 11 Silverberg E, Holleb A. I. Cancer Statistics, 1971. Ca 21: 13-31. 1971;
  • 12 Britten A. How many hemophiliacs are there?. Hemo 04: 1-5. 1971;
  • 13 Bouhasin J. D, Monteleone P, Altay C. Role of the lymphocyte in antihemophilic globulin production: A rise in antihemophilic globulin levels in a hemophilic subject with acute lymphoblastic leukemia. J. Lab. clin. Med 78: 122-129. 1971;
  • 14 Rosenthal R. L, Sloan E. Elevated factor VIII activity in acute leukemia. Fed. Proc 26: 487 1967;
  • 15 Shulman N. R, Marder V. J, Hiller M. C. A New Method for Measuring In Vivo Concentrations of Factor VIII Applied in Distribution and Survival Studies and in Detecting Factor VIII Inhibitors. Brinkhous K. M. (Ed.), The Hemophilias. 29 Univ. N. Carolina Press; Chapel Hill: 1964
  • 16 Jacobson S. C, Hershgold E. J. Human Antihemophilic Factor (F-VIII) Labeled with 1-125 or C14: Biochemical and Metabolic Properties. Clin. Res 18: 177 1970;
  • 17 Didisheim P, Trombold J. S, Vandervoort R. L. E. Fibrinogen and factor V deficiencies in acute promyelocytic leukemia (APL). Fed. Proc 22: 213 1970;
  • 18 Green D. Factor VIII (antihemophilic factor). J. chron. Dis 23: 213-225. 1970;
  • 19 McKay D. G, Müller-Bergbaus G. Therapeutic implications of disseminated intravascular coagulation. Amer. J. Card 20: 392-410. 1967;
  • 20 Phillips L. L. Alterations in the blood clotting system in disseminated intravascular coagulation. Amer. J. Card 20: 174-184. 1967;
  • 21 Verstraete M, Vermylen C, Vermylen J, Vandenbroucke J. Excessive consumption of blood coagulation components as cause of hemorrhagic diathesis. Amer. J. Med 38: 899-908. 1965;
  • 22 Johnson A. J, Merskey C. Diagnosis of diffuse intravascular clotting: its relation to secondary fibrinolysis and treatment with heparin. Thrombos. Diathes. haemorrh. (Stuttg). (Suppl. 20) 161-172. 1966;